The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

Exclusion Criteria

• •Diabetic patients
• •Pregnant or lactated women
• •Patient with history of severe thrombosis
• •Concomitant radiotherapy
• •Known hypersensitivity yo thalidomide, palonosetron, or dexamethasone.
• •Concurrent administration of any other drug which affect antiemetic effect evaluation such as proton pump inhibitor, H2 blocker, amifostine, sedative drugs
• •Cyclophosphamide, hydroxydaunomycin, Oncovin, and prednisone (CHOP )regiment or taxanes-based regiment
• •Existing emesis within 24 hours before chemotherapy administration
• •Symptomatic brain metastasis or suspected clinical brain metastasis
• •Serious uncontrolled systemic illness or medical condition: congestive heart failure, unstable angina, history of documented myocardial infarction within 6 months, uncontrolled hypertension and high risk uncontrollable arrhythmias; Obvious neurological or mental abnormalities including mental disorder, epileptic dementia, which affect compliance; Uncontrolled acute infections; Uncontrolled peptic ulcer or other contraindication for corticosteroid therapy.
• •Inability to take or absorb oral medicine
• •Concurrent administration of any other investigational drug, or have been enrolled in other clinical trial with investigational drug treatment within the 30 days of start of study treatment
• •Unsuitable for the study or other chemotherapy determined by investigator